The Gut-liver Axis in Cholangiopathies: Focus on Bile Acid Based Pharmacological Treatment

Overview

Journal Curr Opin Gastroenterol

Specialty Gastroenterology

Date 2022 Jan 16

PMID 35034082

Authors

Marica Cariello

Raffaella M Gadaleta

Antonio Moschetta

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: This review analyses the main features of primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) and provides an overview of the currently available (bile acid) bile acid related treatments.

Recent Findings: In PBC, biliary injury is the consequence of a dysregulated intrahepatic and systemic immune response. Given the close association between PSC and inflammatory bowel disease (IBD), the microbiota represents an important factor in the development of PSC. Bile acid based pharmacological treatments could represent promising therapeutic strategies in the management of cholangiopathies.

Summary: Cholangiopathies include a spectrum of diseases resulting in cholestasis, an impairment of bile flow in the biliary tree, leading to biliary obstruction and damage as well as liver inflammation and fibrosis. PSC and PBC are highly heterogeneous cholangiopathies and progressive disorders with defined pathophysiological mechanisms. Curative treatments have not been established, and although their prevalence is low, they are a frequent indication for liver transplantation in the advanced stages of cholangiopathies. These diseases still present with unmet therapeutic strategies, also taking into account that on average 30-40% of patients undergoing liver transplantation will have recurrence of the original illness.

Citing Articles

Glycine-β-Muricholic Acid Improves Liver Fibrosis and Gut Barrier Function by Reducing Bile Acid Pool Size and Hydrophobicity in Male Knockout Mice.

Hasan M, Chen J, Wang H, Du Y, Clayton Y, Gu L Cells. 2023; 12(10).

PMID: 37408204 PMC: 10216635. DOI: 10.3390/cells12101371.

Costunolide alleviated DDC induced ductular reaction and inflammatory response in murine model of cholestatic liver disease.

Hao J, Shen X, Lu K, Xu Y, Chen Y, Liu J J Tradit Complement Med. 2023; 13(4):345-357.

PMID: 37396159 PMC: 10310871. DOI: 10.1016/j.jtcme.2023.02.008.

Animal Models for Autoimmune Hepatitis: Are Current Models Good Enough?.

Christen U, Hintermann E Front Immunol. 2022; 13:898615.

PMID: 35903109 PMC: 9315390. DOI: 10.3389/fimmu.2022.898615.

References

Bjornsson E, Olsson R, Bergquist A, Lindgren S, Braden B, Chapman R . The natural history of small-duct primary sclerosing cholangitis. Gastroenterology. 2008; 134(4):975-80. DOI: 10.1053/j.gastro.2008.01.042. View

Allegretti J, Kassam Z, Carrellas M, Mullish B, Marchesi J, Pechlivanis A . Fecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis: A Pilot Clinical Trial. Am J Gastroenterol. 2019; 114(7):1071-1079. DOI: 10.14309/ajg.0000000000000115. View

Hasegawa S, Yoneda M, Kurita Y, Nogami A, Honda Y, Hosono K . Cholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents. Drugs. 2021; 81(10):1181-1192. PMC: 8282588. DOI: 10.1007/s40265-021-01545-7. View

Abarbanel D, Seki S, Davies Y, Marlen N, Benavides J, Cox K . Immunomodulatory effect of vancomycin on Treg in pediatric inflammatory bowel disease and primary sclerosing cholangitis. J Clin Immunol. 2012; 33(2):397-406. PMC: 3565076. DOI: 10.1007/s10875-012-9801-1. View

Ruhlemann M, Liwinski T, Heinsen F, Bang C, Zenouzi R, Kummen M . Consistent alterations in faecal microbiomes of patients with primary sclerosing cholangitis independent of associated colitis. Aliment Pharmacol Ther. 2019; 50(5):580-589. PMC: 6899739. DOI: 10.1111/apt.15375. View

Gulamhusein A, Hirschfield G . Primary biliary cholangitis: pathogenesis and therapeutic opportunities. Nat Rev Gastroenterol Hepatol. 2019; 17(2):93-110. DOI: 10.1038/s41575-019-0226-7. View

Chang J, Go S, Verhoeven A, Beuers U, Oude Elferink R . Role of the bicarbonate-responsive soluble adenylyl cyclase in cholangiocyte apoptosis in primary biliary cholangitis; a new hypothesis. Biochim Biophys Acta Mol Basis Dis. 2017; 1864(4 Pt B):1232-1239. DOI: 10.1016/j.bbadis.2017.09.022. View

Karlsen T, Folseraas T, Thorburn D, Vesterhus M . Primary sclerosing cholangitis - a comprehensive review. J Hepatol. 2017; 67(6):1298-1323. DOI: 10.1016/j.jhep.2017.07.022. View

Lindor K, Gershwin M, Poupon R, Kaplan M, Bergasa N, Heathcote E . Primary biliary cirrhosis. Hepatology. 2009; 50(1):291-308. DOI: 10.1002/hep.22906. View

10.

Heathcote E . Evidence-based therapy of primary biliary cirrhosis. Eur J Gastroenterol Hepatol. 1999; 11(6):607-15. DOI: 10.1097/00042737-199906000-00005. View

11.

Kevans D, Tyler A, Holm K, Jorgensen K, Vatn M, Karlsen T . Characterization of Intestinal Microbiota in Ulcerative Colitis Patients with and without Primary Sclerosing Cholangitis. J Crohns Colitis. 2015; 10(3):330-7. PMC: 4957469. DOI: 10.1093/ecco-jcc/jjv204. View

12.

Quraishi M, Acharjee A, Beggs A, Horniblow R, Tselepis C, Gkoutos G . A Pilot Integrative Analysis of Colonic Gene Expression, Gut Microbiota, and Immune Infiltration in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Association of Disease With Bile Acid Pathways. J Crohns Colitis. 2020; 14(7):935-947. PMC: 7392170. DOI: 10.1093/ecco-jcc/jjaa021. View

13.

Razumilava N, Gores G . Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol. 2012; 11(1):13-21.e1. PMC: 3596004. DOI: 10.1016/j.cgh.2012.09.009. View

14.

Assis D, Abdelghany O, Cai S, Gossard A, Eaton J, Keach J . Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis: A Human Pilot Study. J Clin Gastroenterol. 2016; 51(2):e11-e16. PMC: 5218875. DOI: 10.1097/MCG.0000000000000591. View

15.

Lee Y, Schmidt D, Cummins C, Choi M, Peng L, Zhang Y . Liver receptor homolog-1 regulates bile acid homeostasis but is not essential for feedback regulation of bile acid synthesis. Mol Endocrinol. 2008; 22(6):1345-56. PMC: 2409274. DOI: 10.1210/me.2007-0565. View

16.

Kim I, Ahn S, Inagaki T, Choi M, Ito S, Guo G . Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J Lipid Res. 2007; 48(12):2664-72. DOI: 10.1194/jlr.M700330-JLR200. View

17.

Pircher P, Kitto J, Petrowski M, Tangirala R, Bischoff E, Schulman I . Farnesoid X receptor regulates bile acid-amino acid conjugation. J Biol Chem. 2003; 278(30):27703-11. DOI: 10.1074/jbc.M302128200. View

18.

Combes B, Emerson S, Flye N, Munoz S, Luketic V, Mayo M . Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology. 2005; 42(5):1184-93. DOI: 10.1002/hep.20897. View

19.

Lichtman S, Okoruwa E, Keku J, Schwab J, Sartor R . Degradation of endogenous bacterial cell wall polymers by the muralytic enzyme mutanolysin prevents hepatobiliary injury in genetically susceptible rats with experimental intestinal bacterial overgrowth. J Clin Invest. 1992; 90(4):1313-22. PMC: 443175. DOI: 10.1172/JCI115996. View

20.

Kaplan M, Cheng S, Price L, Bonis P . A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten-year results. Hepatology. 2004; 39(4):915-23. DOI: 10.1002/hep.20103. View